NEW YORK – One Equity Partners (“OEP”), a middle market private equity firm, today announced that it has completed a strategic investment of InfuCare Rx (or “the Company”), a national provider of specialty infusion therapies and comprehensive clinical therapy management services to patients with complex conditions. Financial terms of the private transaction were not disclosed.
InfuCare Rx is pleased to announce its selection as a limited distribution provider of VYVGART™. VVGART™ has been approved by the Food & Drug Administration (FDA) in the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the antiacetylcholine receptor (AChR) antibody. InfuCare Rx is a leading data-driven nationwide specialty infusion provider. […]